



(12) Translation of
european patent specification

(11) NO/EP 2278978 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/575 (2006.01)
A61P 11/06 (2006.01)
A61P 19/02 (2006.01)
A61P 21/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2015.12.21
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.09.02
(86)	European Application Nr.	09767367.7
(86)	European Filing Date	2009.05.28
(87)	The European Application's Publication Date	2011.02.02
(30)	Priority	2008.05.28, US, 56715 P
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
(73)	Proprietor	ReveraGen BioPharma, Inc., 3910 Warner Street, Kensington, MD 20595, US-USA
(72)	Inventor	MCCALL, John, M., 3910 Warner Street, KensingtonMD 20895, US-USA HOFFMAN, Eric, 3910 Warner Street, KensingtonMD 20895, US-USA KANNEBOYINA, Nagaraju, 3910 Warner Street, KensingtonMD 20895, US-USA


(54)	Title	NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE
(56)	References Cited:	EP-A2- 1 236 469 WO-A1-91/19731 WO-A1-99/03503 WO-A1-99/17778 WO-A1-99/32102 WO-A1-99/61030 WO-A1-03/014141 WO-A2-02/43785 GB-A- 1 480 763 GB-A- 2 131 811 US-A- 4 645 763 US-A- 5 990 099 US-A- 6 011 023 US-A- 6 090 794 MCNATT LORETTA G ET AL: "ANGIOSTATIC ACTIVITY OF STEROIDS IN THE CHICK EMBRYO CAM AND RABBIT CORNEA MODELS OF NEOVASCULARIZATION", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, MARY ANN LIEBERT, INC., NEW YORK, NY, US, vol. 15, no. 5, 1 January 1999 (1999-01-01), pages 413-423, XP008069358, ISSN: 1080-7683 H. ASAHARA ET AL. BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL vol. 37, no. 5, 1995, pages 827 - 832 YANG, C.C.: 'Immunolocalization of transcription factor NF-kappa B in inclusion-body myositis muscle and at normal human neuromuscular junctions' NEUROSCIENCES LETTERS vol. 254, 1998, pages 77 - 80, XP008144863 BAUERLE, P. A.: 'NF-kB: Ten Years After' CELL vol. 87, pages 13 - 20, XP000962411

- HEIER CHRISTOPHER R ET AL: "VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.", EMBO MOLECULAR MEDICINE OCT 2013, vol. 5, no. 10, October 2013 (2013-10), pages 1569-1585, ISSN: 1757-4684
- DI MEGLIO PAOLA ET AL: "Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation", ARTHRITIS & RHEUMATISM, vol. 52, no. 3, March 2005 (2005-03), pages 951-958, ISSN: 0004-3591
- BAO ZHANG ET AL: "A Novel Antiinflammatory Role for Andrographolide in Asthma via Inhibition of the Nuclear Factor-kappa B Pathway", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 179, no. 8, April 2009 (2009-04), pages 657-665, ISSN: 1073-449X
- POYNTER MATTHEW E ET AL: "NF-kappa B activation in airways modulates allergic inflammation but not hyperresponsiveness.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 2004, vol. 173, no. 11, 1 December 2004 (2004-12-01), pages 7003-7009, ISSN: 0022-1767
- IZMAILOVA ELENA S ET AL: "Use of molecular Imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis", ARTHRITIS & RHEUMATISM, vol. 56, no. 1, January 2007 (2007-01), pages 117-128, ISSN: 0004-3591

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse for anvendelse for behandling av symptomene på en sykdom valgt fra gruppen bestående av artritt og astma, hvor nevnte forbindelse har strukturformelen:



2. Forbindelse for anvendelse ifølge krav 1, hvor nevnte sykdom er astma.
3. Forbindelse for anvendelse ifølge krav 1, hvor nevnte sykdom er artritt.